Saturday 04/April/2026 – 12:26 AM
Researchers in the field of biomedical engineering have developed injectable microparticles that contribute to reducing bleeding by more than fifty percent, which represents a huge medical breakthrough that makes infant surgery safer and eliminates the need for blood transfusions from adults, which may cause serious complications that threaten the lives of newborns.
According to medical
Risks of transfusing adult blood to children
Dr. Ashley Brown, professor of biomedical engineering and the lead author of the study, explained that the process of blood clotting and stopping bleeding differs radically between adults and newborns, and this difference creates a real crisis when performing infant surgery, as doctors usually rely on blood transfusions from adult donors to replace the blood lost during the operation, but this procedure may lead to excessive blood clotting, which increases the possibility of dangerous clots forming in the lungs or other parts of the body and exposes the child’s life to the risk of certain death.
Gel particles that mimic platelets
To overcome these catastrophic risks, the research team developed an innovative material based on tiny particles equipped with a series of amino acids that play a crucial role in the process of stopping bleeding in children. These particles are characterized by their superior ability to absorb water and transform into a spongy gelatinous material that mimics the mechanical properties of natural platelets, which enhances the ability of amino acids to form strong networks of proteins that come together to stop bleeding very effectively and quickly, to ensure the stability of the patient’s condition during complex infant surgery.
Success of laboratory experiments and aspirations for the future
The researchers conducted a series of precise experiments using microfluidic devices to test the effectiveness of these molecules in blood plasma. The results showed a noticeable superiority in the plasma of children compared to adults. Experiments on genetically modified mice also demonstrated that this technology outperformed all currently available medical options in reducing blood loss. In the next steps, scientists seek to ensure that there are no unexpected risks before using these molecules in clinics and hospitals, as this innovation represents a low-cost solution that guarantees the success of infant surgery and reduces dependence on expensive blood products.
